Novel Wheat Allergens
AssigneePhadia AB
InventorsRudolf Valenta, Claudia Constantin, Santiago Quirce
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of IgE-mediated allergy, particularly occupational asthma such as bakers asthma. More specifically the invention relates to the identification of a novel wheat allergen and the use thereof in therapy and diagnosis of IgE-mediated allergy. Furthermore the present invention provides the use of known peptides and proteins in therapy and diagnosis. The invention also relates to methods for diagnosis and treatment of IgE-mediated allergy in mammals.
Claims20
An isolated polypeptide comprising the amino acid sequence according to SEQ ID NO:
- 2, 8 or 10.
An isolated polypeptide comprising the amino acid sequence according to SEQ ID NO:
- 4 or 6 or a fragment or variant thereof sharing epitopes for antibodies with said polypeptide, for use in therapy or diagnosis.
An isolated polypeptide comprising the amino acid sequence according to SEQ ID NO:
- 4 or 6 or a fragment or variant thereof sharing epitopes for antibodies with said polypeptide, for use in therapy or diagnosis of IgE-mediated allergy.
Pharmaceutical composition comprising a polypeptide having the amino acid sequence according to SEQ ID NO:
- 2, 4, 6, 8 or 10 or a hypoallergenic form of said polypeptide that is modified to abrogate or attenuate its IgE binding response, and optionally pharmaceutically acceptable excipients, carriers, buffers and/or diluents.
Method for producing an allergen composition comprising the step of adding a polypeptide having the amino acid sequence according to SEQ ID NO:
- 2, 4, 6, 8 or 10 or a fragment or variant thereof sharing epitopes for antibodies with said polypeptide, to a composition comprising an allergen extract and/or at least one purified allergen component.
A method for in vitro diagnosis of IgE-mediated allergy comprising the steps of
- contacting a body fluid sample from a mammal suspected of having IgE-mediated allergy with at least one polypeptide having the amino acid sequence according to SEQ ID NO:
- 2, 4, 6, 8 or 10 or a fragment or variant thereof sharing epitopes for antibodies with said polypeptide;
- and
- detecting the presence, in the sample, of IgE antibodies specifically binding to said polypeptide or polypeptides;
- wherein the presence of such antibodies specifically binding to said polypeptide or polypeptides is indicative of IgE-mediated allergy.
Dependencies are inferred from the claim text.